Renal and vascular actions of urotensin II  by Ashton, N.
Renal and vascular actions of urotensin II
N Ashton1
1Faculty of Life Sciences, University of Manchester, Manchester, UK
The peptide hormone urotensin II (UII) has been highly
conserved through the vertebrates from fish to humans. As it
was shown to be the endogenous ligand for the mammalian
orphan G-protein-coupled receptor GPR14, now renamed
the UT receptor, interest in UII physiology has grown.
Initial observations of a potent vasoconstrictor effect have
been tempered with the subsequent revelation of an
endothelium-dependent vasodilator action. These complex
and contrasting vascular actions are both species- and
vascular bed-specific. UII also plays a role in body fluid
regulation in lower vertebrates, and it now appears that this
extends to mammals. The kidney is a major source of both
circulating and urinary UII. UII is found in both the proximal
tubules and collecting ducts; the UT receptor is localized
primarily to the renal medulla, with greatest expression in
the inner medullary collecting ducts. Infusion in rats
produced conflicting results: exogenous UII has been shown
to increase glomerular filtration rate (GFR) and excretion of
water and sodium, but also to reduce the same variables.
Inhibition of UT receptor activity with the antagonist urantide
resulted in an increase in GFR, diuresis, and natriuresis,
suggesting that endogenous UII exerts a tonic influence on
basal renal function. UII may also play a role in renal disease,
being elevated in the circulation or urine of patients with
renal failure and in experimental models of cardiovascular
disease such as the spontaneously hypertensive rat. It
remains to be established whether these changes represent
an underlying primary cause or a compensatory response.
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Urotensin II (UII) was originally identified as one of a
number of peptide hormones secreted by the fish caudal
neurosecretory system. Synthesized in Dahlgren cells of the
caudal spinal cord and released from the urophysis, a
neurohemal organ unique to teleost fish, UII has been shown
to contract vascular smooth muscle not only in fish but also
in mammalian tissues.1 However, it was not until the
discovery by Coulouarn et al.2 that prepro-UII is expressed
in human spinal cord, and peripheral tissues including the
kidney, that a role for this peptide hormone was suspected in
humans. Shortly after this report, Ames et al.3 published their
landmark paper in the field, which demonstrated that goby
UII binds to the human orphan G-protein-coupled receptor
GPR14, now designated the UT receptor. Identification of the
human form of UII (hUII)2 revealed that it shares the cyclic
hexapeptide sequence, Cys-Phe-Trp-Lys-Tyr-Cys, that is
conserved across all species1 (Figure 1) and confers biological
activity upon the molecule.4
Initial attention focused on the vascular actions of UII,
not least because of its extremely potent action in non-
human primates. In vitro, hUII evoked contraction of a wide
range of non-human primate arterial vessels; however venous
vessels were unresponsive. However, Ames et al.3 observed
less profound responses in rats, with only the thoracic aorta
responding to hUII in vitro. In vivo, bolus injection of hUII
led to myocardial depression, circulatory collapse, and
death in the cynomolgus monkey.3 Subsequent studies have
shown that the vasoactive properties of UII are more
complex, with differences both between species and between
vascular beds of the same species (reviewed by Douglas
et al.;5 Table 1). Over the past few years, UII has emerged as
an in vitro spasmogen, up to 100-fold more potent than
endothelin I in arteries isolated from rats, humans, and a
number of other mammalian species. Its pseudo-irreversible
binding properties to the UT receptor have led to the
suggestion that UII may function as a chronic regulator of
basal vascular tone, rather than a short-term regulator of
vascular resistance.5 UII has also been shown to act as
vasodilator: this action was endothelium-dependent,
suggesting that vasodilatation is mediated via UT receptors
on the endothelium whereas vasoconstriction is mediated via
UT receptors on smooth muscle cells.5 These contrasting
effects suggest that UII plays a more complex role in the
regulation of vascular tone than initial reports suggested,
with UII now emerging as both a paracrine and an endocrine
factor.
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Despite the growing interest in mammalian UII physio-
logy, one aspect that has received little attention to date is its
potential influence on renal function. Evidence that such a
role might exist comes from studies in teleost fish, which
show that UII contributes to their osmoregulatory physio-
logy. A number of reports have implicated UII in the
conservation of water,6 sodium, and chloride7 in fish species.
The euryhaline flounder, Platichthys flesus, is able to
osmoregulate and survive in both seawater and fresh water.
When subjected to the hypo-osmotic challenge of a transfer
from seawater to fresh water, plasma UII concentration fell
rapidly, only returning to pre-transfer levels once the fish had
adapted to the new osmotic environment over 72 h later.6
This is consistent with the notion that UII supports survival
in hypertonic media by promoting water retention.1 UII has
also been shown to regulate epithelial sodium transport.
Thus, in absorptive tissues of teleost fish, such as urinary
bladder and intestine, UII stimulated active sodium and
chloride uptake from luminal fluid. Whereas in secretory
tissues, such as opercular skin, UII inhibited active sodium
and chloride transport.7 These observations demonstrate that
UII can directly affect epithelial ion transport in fish and
influence body fluid homeostasis, highlighting that UII may
also influence renal function in mammals.
UII AND UT EXPRESSION IN THE KIDNEY
The kidney appears to be a major source of UII synthesis in
mammalian species. Prepro-UII mRNA expression has been
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Figure 1 | The structure of human, rat, and goby UII. All known isoforms share a conserved cyclic hexapeptide sequence, Cys-Phe-Trp-Lys-
Tyr-Cys. A disulfide bridge between the two cysteine residues produces a cyclic region which confers biological activity on the molecule.
It is this common sequence that is recognized by the UT receptor; hence, fish and mammalian isoforms bind with similar affinity to the
receptor. The structure of URP is also shown. This octapeptide, which is identical in humans and rats, also shares the conserved cyclic
Cys-Phe-Trp-Lys-Tyr-Cys sequence with UII and is able to bind to the UT receptor.
Table 1 | Diverse vascular responses of mammalian species
to UII
Vessel Species Response
In vitro
Thoracic aorta Rat, rabbit, pig, marmoset Constrict
Carotid artery Rat Constrict
Renal artery Cynomolgus monkey Constrict
Mesenteric artery Cynomolgus monkey Constrict
Mesenteric artery Rat Relax
Femoral artery Cynomolgus monkey Constrict
Basilar artery Cynomolgus monkey Constrict
Basilar artery Rat Relax
Coronary artery Rat, pig Relax
Coronary artery Cynomolgus monkey, dog Constrict
Pulmonary artery Human Relax
Pulmonary artery Human, rat, rabbit,
cynomolgus monkey
Constrict
Abdominal adipose
tissue artery
Human Relax
Saphenous vein Human Constrict
Umbilical vein Human Constrict
Jugular vein Rabbit Constrict
In vivo
Mesenteric artery Rat Relax
Hindquarter vascular bed Rat Relax
Mesenteric artery Cynomolgus monkey Constrict
Carotid artery Cynomolgus monkey Constrict
It is notable that vascular beds from the same species show different responses.
Furthermore, the same vascular beds in different species differ in their response to
UII. This is most striking when comparing the effects of UII in vivo: in the
cynomolgus monkey, UII causes profound vasoconstriction, yet in the rat it causes
vasodilatation and a reduction systemic blood pressure. Data from Douglas et al.,5
Maguire and Davenport,31 Camarda et al.,32 and Douglas et al.33
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identified in human,2,8 primate, and mouse kidneys.9
Immunoreactive UII expression has been described in human
renal blood vessels.10 This was limited to the arterial vessels,
which expressed UII in both endothelial and smooth muscle
cells. In the tubule itself, the greatest level of expression was
found in the distal and collecting tubules.10 We observed a
somewhat different pattern of UII expression in the rat
kidney, with immunostaining present in the proximal
tubules, outer, and inner medullary collecting ducts. This is
consistent with the observation that UII mRNA expression
was significantly higher in the medulla in comparison with
the cortex.11 UII is also present in human8 and rat11 urine at
concentrations greatly exceeding that in plasma. Human UII
clearance equalled or exceeded that of creatinine in normal
human subjects, leading to the suggestion that urinary UII is
primarily derived from a renal source.8 Measurement of
arteriovenous concentration gradients revealed net secretion
of UII into the circulation of the anesthetized sheep by the
kidneys, as well as the heart and liver.12 Thus, renally derived
UII may act not only as a local paracrine/autocrine factor in
the kidney, but may also play a role as a circulating
endocrine.
UT mRNA is expressed in human,8 monkey, and mouse
kidneys.9 [125I]hUII-binding sites have also been identified in
the Sprague–Dawley rat kidney by autoradiography.13 The
majority of binding sites were found in the medulla, with
very little cortical binding. This agrees with our observations,
by immunohistochemistry, of UT expression in thin ascend-
ing limbs and inner medullary collecting ducts, with only
occasional immunostaining in glomerular arterioles.11 We
also reported that medullary UT mRNA expression was
significantly greater than that in the cortex.11 Several ligand-
binding studies have concluded that UII interacts with a
single class of binding site. Competition binding experiments
showed that several isoforms of UII (goby, rat, mouse, and
porcine A and B) displaced hUII radioligand from mouse and
monkey UT receptors transfected into HEK-293 cells with
comparable Ki values and Hill coefficients approaching
unity.9 A single class of binding sites for hUII has been
described in the rat outer medulla, with an apparent dissoci-
ation constant (Kd) of 1.970.9 nM and a maximum binding
capacity (Bmax) of 408747 amol mm
2.13 Taken together,
these data suggest that UII may possess renovascular
effects, whereas any potential tubular actions are likely to
be limited to the loop of Henle´ and distal nephron.
The UT receptor has also been shown to bind another
peptide, urotensin-related peptide (URP). This octapeptide,
identified in humans, mice, and rats,14 shares the cyclic
hexapeptide sequence Cys-Phe-Trp-Lys-Tyr-Cys with UII
(Figure 1). Despite the similarity of the mature peptides,
the precursor proteins show little sequence homology,
consistent with the disparate locations of the human UII
and URP genes at 1p36 and 3q29, respectively. In competi-
tion binding studies, URP bound to both hUT and rUT
receptors with higher affinity than that of hUII (IC50 in CHO
cells expressing hUT receptors was 2.8 nM for URP vs 12 nM
for hUII). In vivo, URP induced a hypotensive response in
anesthetized rats of similar magnitude to that induced by
rUII. Prepro-URP was identified in human kidney, although
not in rat kidney;14 however, we have reported11 that the rat
kidney expresses URP mRNA at levels comparable with that
of rUII mRNA. Hence, URP may also activate renal UT
receptors and potentially influence renal function in
mammals.
RENAL ACTIONS OF UII
There have only been a few reports of the effects of UII on
renal function in mammals and these have had conflicting
outcomes (Figure 2). We have shown recently11 that bolus
injections of rat UII (rUII) in the low pmol/100 g body
weight range produced dose-related reductions in glomerular
filtration rate (GFR), which were accompanied by reductions
in both urine flow and sodium excretion rates. Preliminary
studies in our laboratory show that continuous infusion of
rUII over the same concentration range also induced a fall in
GFR and an increase in the fractional excretion of sodium
(AES Abdel-Razik, RJ Balment, and N Ashton, unpublished
observations). However, Ovcharenko et al.15 saw only modest
reductions in GFR and no change in sodium excretion in rats
injected with hUII in the low nmol/kg dose range. This
contrasts markedly with the observations of Zhang et al.16
who reported an increase in GFR and a diuresis and
natriuresis following continuous intrarenal infusion of hUII
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Figure 2 | UII stimulates a number of target organs in mammals,
including humans. However, its principal actions are directed
towards the control of blood pressure, through effects on the
cardiovascular and renal systems. Abbreviations: ACTH,
adrenocorticotrophic hormone; BP, blood pressure; CO, cardiac
output; GFR, glomerular filtration rate; HR, heart rate.
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in the low pmol/kg range, again in the rat. These differences
could reflect dose-related responses or the effect of route of
administration. However, Douglas et al.5 propose another
possibility which may account for much of the variability
reported here and in the UII literature as a whole. They
suggest that most UT receptors are occupied by endogenous
UII and, as a result, only a few unoccupied receptors are
available to bind exogenous UII. This lack of a spare receptor
reserve leads to the variability and low efficacy observed
across many studies.
One way to overcome the lack of receptor reserve and
expose the influence of endogenous UII is through the use of
a selective UT receptor antagonist. The most potent UT
receptor antagonist available to date is urantide, [Pen5,
DTrp7, Orn8]hU-II(4–11), a derivative of hUII.17 Adminis-
tration of urantide in vivo has provided evidence of a
heretofore unsuspected role for UII in the regulation of renal
function. Continuous infusion of urantide into the rat, at a
dose shown to inhibit the vascular actions of exogenous UII,
resulted in an increase in GFR, coupled with a diuresis and
natriuresis.11 Fractional excretion of sodium was 44% higher
in the urantide-treated group; however, this difference did
not reach statistical significance. Thus, it remains unclear
whether the natriuresis was due entirely to changes in GFR or
if endogenous UII also exerts a direct action on the tubule.
Given that UII has been shown to stimulate epithelial sodium
transport in fish7 and that the UT receptor is expressed in the
distal nephron of the rat,11 it is tempting to speculate that UII
does have an effect on the tubule itself. Regardless of the
site(s) of action, these data strongly suggest that endogenous
UII exerts a tonic influence on renal function in the rat.
Whether this is the case in humans remains to be determined.
UII IN RENAL DISEASE
A pathophysiological role for UII has been implicated in a
number of renal diseases, although it is not yet clear whether
it has a causative or protective influence. Patients with renal
dysfunction (primarily due to glomerulonephritis or diabetes
mellitus) have been reported to have plasma UII concentra-
tions two- to three-fold higher than those of controls.18
Similarly, patients with diabetic nephropathy have been
shown to have elevated plasma and urinary UII concentra-
tions.19 This was associated with a 64-fold increase in renal
UII expression and a 2000-fold increase in UT expression.20
Plasma UII has also been reported to be elevated in patients
with end-stage renal disease.21 Interestingly, plasma UII
concentration was inversely related to sympathetic activity
and brain natriuretic peptide (a marker of left ventricular
hypertrophy), implying that high plasma UII is associated
with relative cardiovascular protection in end-stage renal
disease. This was confirmed in a follow-up study in which
plasma UII concentration was shown to be inversely related
to fatal and non-fatal cardiovascular events in patients with
end-stage renal disease, leading the authors to suggest that
UII is vasculoprotective in this group.22 In contrast, chronic
heart failure (CHF) patients without reported concurrent
renal disease had 43% higher plasma UII concentrations
compared with controls.23 Furthermore, plasma UII was
positively correlated with the severity of CHF and both brain
natriuretic peptide and big endothelin 1 as markers of left
ventricular hypertrophy. One possible explanation for this
apparent anomaly is that the study in end-stage renal disease
patients documented all cardiovascular events (including
angina, myocardial infarction, arrhythmia, heart failure,
ischemic events, and stroke) rather than CHF alone, so it is
possible that the relationship between plasma UII and
cardiovascular events is disease-specific.
There is also evidence from experimental animal models
that UII may have some role in cardiovascular disease. CHF is
associated with impaired renal function and a reduction in
GFR: UII was shown to induce a marked increase in renal
blood flow and GFR in a rat model of CHF.15 This effect was
nitric oxide-dependent, suggesting that UII can act as a
vasodilator on the renal vasculature. Zhang et al.16 reached a
similar conclusion after demonstrating that hUII induced an
endothelium-dependent vasodilatation of the rat renal artery,
which was inhibited by NG-nitro-L-arginine methyl ester.
This was confirmed using a fluorescent NO indicator, 4,5-
diaminofluorescein diacetate, which showed that hUII
induced NO production in renal artery endothelium.
Changes in UII expression and activity have also been
reported in the spontaneously hypertensive rat (SHR). The
plasma UII concentration was almost twofold higher in SHR
compared with control Wistar–Kyoto (WKY) rats.11 This is
consistent with elevated urinary UII concentrations observed
in hypertensive patients.8 We also observed greater UT
mRNA expression in the medulla of SHR, with a similar
tendency for UII mRNA expression.11 Interestingly, URP
mRNA expression was reduced by comparison with WKY
rats, implying that there is an increase in the UII/URP ratio
in the SHR kidney. The vascular response of SHR to UII
administration is also enhanced: bolus intravenous injection
of hUII produced a greater fall in blood pressure in SHR in
comparison with WKY rats.24 These data suggest that the UII
system is upregulated in SHR with established hypertension;
however, whether this is cause or effect remains to be
determined.
These observations in the SHR raise an important point
that must be taken into account when making comparisons
across species and even different strains of the same species.
Disa et al.13 noted that the low-affinity binding of [125I]hUII
to renal membranes was much lower in both WKY and SHR
when compared with Sprague–Dawley rats. We observed
similar quantitative differences in UII, URP, and UT mRNA
expression between Sprague–Dawley rats and that of WKY
and SHR. UT mRNA expression in the cortex of WKY and
SHR was eightfold lower and medullary expression was 11-
fold lower than that in Sprague–Dawley rats.11 The in vivo
response to bolus intravenous UII also differs between rat
strains: at 3–10 ng/kg, UII lowered blood pressure in WKY
and Sprague–Dawley rats by 10–20%, whereas similar doses
reduced blood pressure in Lewis rats by 50%.13 Thus, caution
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must be taken when comparing data from different rat strains
as it appears that activity of the UII system varies
considerably.
UT RECEPTOR ANTAGONISTS
Altered UII expression in disease states has prompted the
development of a number of UT receptor antagonists
(reviewed by Carotenuto et al.25). Several peptide antagonists
have been identified which share a common cyclic region,
similar to the conserved sequence of UII (Figure 1). This
comprises D/LCys-X-D/LTrp-Orn/Lys-Z-Cys, where X is either
Phe, [3-pyridyl]Ala, [4-aminophenyl]Ala, or Tyr and Z is
either Tyr, Val, or tert-Leu. Of these compounds, urantide is
the most potent peptide antagonist developed to date.17 It
acts as a pure antagonist of the rat UT receptor, with a pA2 of
8.2 in the rat-isolated thoracic aorta bioassy;17 however, it has
been shown to act as an agonist (pEC50 8.1) in a [Ca
2þ ]i
mobilization assay in CHO cells expressing the hUT
receptor.26 A number of non-peptide compounds have also
been developed; these feature a basic amino group and at
least two aromatic moieties. The most potent of these is the
4-ureido-quinoline derivative, palosuran (ACT-058362).27
Palosuran is selective for the human UT receptor, with an
IC50 of 3.6 nM for hUT compared with 1475 nM for rUT. A
series of diarlsulfonamide derivatives have been described
recently, which appear to be potent antagonists of several
forms of the UT receptor. One example, SB-706375, was
shown to inhibit [125I]hUII binding to the UT receptor in
SJRH30 cells (Ki 5.4 nM) as well as rodent, feline, and primate
recombinant UT receptors (Ki 4.7–20.7 nM).
28
Application of these and other compounds in a variety of
disease models has shown that UT antagonism has potential
therapeutic benefit. Thus, SB-611812, an arylsulfonamide UT
antagonist, has been used to show that UII-induced re-
stenosis can be reduced in rat carotid arteries following
balloon angioplasty.29 Administration of palosuran to
streptozotocin-treated rats improved survival, increased
insulin, and reduced the progression of renal damage.30
Similar effects were not seen in preliminary trials in patients
with diabetic nephropathy, but further studies are underway
to refine the dose regime in an attempt to improve the
outcome. The therapeutic potential of UT receptor antago-
nists has yet to be fully realized, but it seems likely that they
will be of clinical use in the treatment of hypertension, heart
failure, and renal disease.
CONCLUSIONS
In less than a decade since the discovery that UII is the
endogenous ligand for the human orphan receptor GPR14,
significant advances have been made in our understanding of
the physiology of UII in mammals. UII has emerged as the
most potent natural vasoconstrictor peptide, yet it also
evokes endothelium-dependent vasodilatation. These effects
are both species- and vascular bed-specific, suggesting that
although some of the actions of UII have been conserved
through evolution, there is also divergence. Rather less is
known about UII’s actions on the kidney, but recent studies
from our lab and others have shown that UII influences GFR
and the excretion of water and sodium. A direct effect on the
tubular handling of sodium has yet to be demonstrated
unequivocally, but circumstantial evidence points to the
distal nephron as a potential site of action. The kidney has
emerged as one of the main sources of UII in both humans
and the rat, where it acts both as a paracrine and a circulating
endocrine factor. Many of the biological effects of UII may
also be induced by URP, which shares the conserved amino-
acid sequence that conveys biological activity. The endogen-
ous stimuli for UII and URP secretion in mammals remain
unknown, so it is not clear whether the two peptides are
released under similar circumstances. Altered UII and UT
expression in renal failure and cardiovascular disease models
suggests that UII may play a role in the diseased kidney;
whether this role is protective or causal remains to be
determined.
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